Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma.
Latest Information Update: 05 Oct 2017
Price :
$35 *
At a glance
- Drugs Decitabine (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
- 30 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 17 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.